Ockham Earns CEO Cancer Gold Standard Accreditation
Cary, NC, October 6, 2011 – Ockham, a leading, global full-service contract research organization (CRO) with a focus in oncology, today announced it has received the CEO Cancer Gold StandardTM Accreditation from the CEO Roundtable on Cancer, recognizing the company’s efforts to reduce cancer risks among employees and their families, while improving their overall health.
According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer at some point during their lifetime. Because of this, Ockham has made it their mission to find life-saving therapies for debilitating diseases like cancer by expediting the oncology drug development. The CEO Cancer Gold StandardTM Accreditation further exemplifies how the company places importance on educating employees on cancer risks and helping employees mitigate these risks.
“Ockham is honored the CEO Roundtable on Cancer has recognized our achievements with this prestigious accreditation. Ockham is dedicated to working with companies to discover new therapies to fight cancer. As a company, it is our duty to do what we can to help fight cancer since this disease touches us all in one way or another.”
Christopher A. Viehbacher, chief executive officer of Sanofi, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals. Today, more than two million employees and family members are benefiting from the vision and leadership of employers who have chosen to become Gold Standard accredited.
The CEO Cancer Gold Standard™ calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting a healthy diet and nutrition; detecting cancer at its earliest stages when outcomes may be more favorable; and providing access to quality care, including participation in cancer clinical trials.
About the Company:
Ockham is a leading global CRO and FSP organization, supplemented by a robust traditional sourcing component, founded in 1986. The company offers a full range of clinical research services for Phase I-IV clinical trials in oncology, as well as other therapeutic areas. Ockham provides its clients with a combination of medical and technical expertise within their tightly controlled clinical studies. Ockham is headquartered in Cary, North Carolina with satellite offices strategically placed around the United States, India and the United Kingdom to serve global customers and operations. For more information about Ockham, visit www.ockham.com.
About The CEO Roundtable on Cancer:
The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to “do something bold and venturesome about cancer within your own corporate families.” The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard, a comprehensive program designed to combat cancer from every angle by focusing on prevention, early detection and quality care. For more information on the CEO Cancer Gold Standard™ and the web-based accreditation process and support, please visit www.CancerGoldStandard.org.
CONTACTS:
Media:
Kelly Morrison
+1 919 380 5689
Business Development:
Michael Baker
+1 919 653 6081
Next Post: Ockham Named to Second Consecutive “Fast 50” List of Triangle-Area Businesses